New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“ ...

Core Viewpoint - Nvidia has divested its shares in Applied Digital, Recursion Pharmaceuticals, and WeRide, indicating a strategic shift in its investment portfolio [1] Group 1: Company Actions - Nvidia disclosed in a filing that it no longer holds shares in Applied Digital, a company focused on digital infrastructure [1] - The company has also exited its investment in Recursion Pharmaceuticals, which specializes in drug discovery [1] - Additionally, Nvidia has divested from WeRide, an autonomous-driving technology company [1]

One of the most important things we can use AI for is to improve human health. I recently spoke with @agarfinks from @FortuneMagazine on the incredible progress we're making @IsomorphicLabs pushing the frontier of AI-powered drug discovery to make the process 10x faster & better! ...

Core Insights - N2OFF, Inc. is focusing on drug discovery and solar energy investments, highlighting a peer-reviewed study on mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunctions [1][2][4] Group 1: Study Overview - The study titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction" was published on December 30, 2025, and examines the expression of 53 SLC25A genes under microgravity conditions [2][3] - The analysis found differential regulation of SLC25A carriers, suggesting their potential as biomarkers for mitochondrial dysfunction [3] Group 2: Company Focus - MitoCareX Bio, a subsidiary of N2OFF, is developing small-molecule drugs targeting mitochondrial carriers, which are crucial for cellular energy metabolism and are involved in various diseases [4][6] - The company utilizes proprietary methods, including the MITOLINE algorithm, to model and validate drug targets within the SLC25A family [4] Group 3: Investment Strategy - N2OFF is also investing in European renewable energy assets, specifically solar projects, under a Ready to Build (RTB) business model [6] - The company is the lead investor in four solar projects across three EU countries, introduced by its subsidiary Solterra Renewable Energy Ltd [6]

Group 1: DraftKings - DraftKings shares lost 8% in value last year and closed 35% below their 2025 peak due to slowing growth and competition from platforms like Kalshi and Polymarket [4] - Concerns about competition disrupting DraftKings' growth are considered overblown, as the brand's recognition and partnerships provide significant marketing advantages [5][6] - DraftKings is diversifying its revenue streams, with casino-style gaming accounting for nearly half of its revenue, which may remind investors of its growth potential [7] Group 2: Recursion Pharmaceuticals - Recursion Pharmaceuticals experienced a 44% pullback last year, but 2026 could be a pivotal year for the company [8] - The company has developed an AI-powered drug discovery platform, Recursion OS, which can analyze 65 petabytes of data to predict drug performance [9]

@IsomorphicLabs today announced a cross-modality and multi-target research collaboration with @JNJInnovation. The partnership brings together Isomorphic’s AI-first approach to drug design with Johnson & Johnson’s expertise in drug discovery to design novel molecules that might otherwise remain undiscovered.Head to the comments for the full announcement. ...

Core Insights - N2OFF, Inc. is focusing on drug discovery and solar energy investments, highlighting a new study on SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunctions [1][4] Group 1: Study Overview - The study titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction" was published on December 30, 2025, and examines the expression of 53 SLC25A genes under microgravity conditions [2] - The analysis found differential regulation of SLC25A carriers, suggesting their potential as biomarkers for mitochondrial dysfunction [3] Group 2: Company Focus and Strategy - MitoCareX Bio, a subsidiary of N2OFF, utilizes proprietary computational methods to model small-molecule modulators targeting the SLC25A family, which are crucial for cellular energy metabolism and cancer therapy resistance [4] - N2OFF owns 100% of MitoCareX Bio and has adopted a strategy focused on European renewable energy assets, currently investing in four solar projects across three EU countries [6]

Core Insights - N2OFF, Inc. is advancing its European portfolio through a partnership with Solterra Renewable Energy Ltd, focusing on solar energy projects in Germany [1][7] - The flagship German solar project is on track for approval in Q3 2026, with no objections during the public consultation phase [3][4] - An amendment to the development agreement has been executed, providing Solterra with $340,000 in advance funding while reducing development fees, potentially increasing profits by approximately $1.7 million [5][10] Project Development - The permitting process for the German solar project is nearing completion, with a clear development timeline maintained [4] - The project has successfully reduced regulatory risks and improved development economics, enhancing long-term project viability [6][7] Financial Implications - The transaction represents an efficient redeployment of capital, improving project economics and increasing embedded equity value [6] - Enhanced monetization optionality is anticipated, with multiple pathways for value realization expected to begin in H2 2026 [10]

Core Insights - N2OFF, Inc. is advancing its European portfolio through a partnership with Solterra Renewable Energy Ltd, focusing on solar energy assets and reducing permitting risks [1][5] Germany Update - The flagship project in Germany is on track for Q3 2026 approval, with no objections received during the public consultation phase, indicating strong regulatory support [9] - An amendment to the development agreement has been executed, providing Solterra with approximately €280,000 in advance funding, resulting in project-level savings exceeding $1.69 million [9] Italy Update - Formal planning applications for Sicilian battery storage projects have been submitted, with approvals targeted for H2 2026, contingent on the absence of material objections [4][9] - N2OFF will evaluate optimal value realization paths, including project sale or construction and operation, based on strategic partner decisions [4] Financial Highlights - The strategic renegotiation in Germany has optimized returns, demonstrating a disciplined and capital-efficient approach to project management [9] - The Italian battery storage projects are positioned for high-upside monetization flexibility, with options for sale or build-and-operate strategies [9]

AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity SACRAMENTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end analysis highlighting the company's strategic positioning, active partnership discussions, and favorable market dynamics as 2025 draws to a close. International Business Times also examined several company-specific ...